TCRX
NASD TScan Therapeutics, Inc.$0.2370 ↑ +0.0264 (+12.54%) Trading Up from the previous close of $0.2106, $0.0060 below the day’s high of $0.2430
- YTD change
- -76.30%
- vs 20-day SMA
- -20.64%
- vs 200-day SMA
- -73.82%
Price ranges
Price & Performance
-0.86 (-80.32%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.4% away from all-time highs of $14.7100
- TCRX is down 76% since the beginning of the year
- TCRX is down 89% over the past 12 months
- TCRX is down 28% over the past 1 month
- 4% of all TCRX investors are betting against TCRX
TCRX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -90.6%.
- Previous minute
- +$0.0007
- Last hour
- -$0.0003
- Last 5 days
- -14.41%
- vs 8-day SMA
- -4.19%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
